[release]Following approval in Sweden, Lobsor eyes US entry for new Lecigon treatment for Parkinson’s Disease

Uppsala, October 8, 2018. Lobsor Pharmaceuticals AB, a privately held Swedish company based in Uppsala today announced that Lecigon®, a new therapeutic system for symptomatic treatment of Advanced Parkinson’s Disease (APD) has been granted marketing authorization by the Swedish Medical Products Agency (MPA). Lecigon® is a pharmaceutical gel formulation containing a combination of levodopa/carbidopa and entacapone for continuous infusion into the small intestine through a newly developed lightweight pump.